Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

Phase 4 Completed 545 enrolled Sanofi Pasteur, a Sanofi Company

Non-randomizedSingle-groupOpen-labelPrevention

Summary

Objectives: To provide safety data on revaccination with ADACEL® vaccine. To describe the immune response to tetanus, diphtheria, and pertussis antigens following revaccination with ADACEL® vaccine 4-5 years after first vaccination.

Timeline

Start: 2006-08
Primary completion: 2008-02
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adacel	Vaccine	0.5 ml	Intramuscular

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

Summary

Timeline

Drugs

Indications